Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
09:15am, Friday, 13'th Dec 2024
Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoim
Buy 6 December Dividend Kings But Watch 22 With 'Safer' Dividends
04:41am, Friday, 13'th Dec 2024
"A Dividend King [is] a stock with 50 or more consecutive years of dividend increases." - suredividend.com. 53 Divided Kings, screened as of December 11, 2024, represented all eleven Morningstar Secto
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever
06:00am, Thursday, 12'th Dec 2024
This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high 50 times.
Betting Big On AbbVie: A Prescription For Growth And Dividends
01:12pm, Wednesday, 11'th Dec 2024
AbbVie Inc. has rebounded from setbacks with a strong pipeline, including the promising Parkinson's drug Tavapadon, which shows blockbuster potential. Key growth drivers like SKYRIZI and RINVOQ are bo
AbbVie Completes Acquisition of Aliada Therapeutics
09:15am, Wednesday, 11'th Dec 2024
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R
Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends
03:42pm, Tuesday, 10'th Dec 2024
"Dividend Aristocrats
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
11:40am, Tuesday, 10'th Dec 2024
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results
AbbVie's third successful Parkinson's trial sets the stage for an eventful 2025
10:52am, Monday, 09'th Dec 2024
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson's disease on Monday and said it's on track to seek approval for the drug from the Food and Drug Administr
Don't Miss The Dividend Train: 2 Top Buys To End 2024
09:04am, Monday, 09'th Dec 2024
Time in the market generally beats timing the market. This can be enhanced by buying low and selling high. Here's how. Being an active investor, I believe that timing individual equities can complemen
AbbVie's Parkinson's disease drug meets main goal in late-stage study
08:10am, Monday, 09'th Dec 2024
AbbVie said on Monday its experimental drug to treat Parkinson's disease met the main goal in a late-stage study.
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
03:00pm, Sunday, 08'th Dec 2024
-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys -CLL is one
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 7, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated resu
Calls of the Day: Toast, Abbvie, Berkshire Hathaway
01:31pm, Thursday, 05'th Dec 2024
The Investment Committee debate the latest Calls of the Day.
